Key result
In STEMI patients without hemodynamic compromise, multivessel PCI was associated with a 30-day mortality of 2.8%, compared to 6.3% for IRA-only treatment and 1.3% for single vessel disease (P=0.023).
Why the study?
Does multivessel PCI improve mortality compared to IRA-only PCI in STEMI patients with multivessel disease?
Population
745 patients treated with primary PCI for <24 hr STEMI between 2004-2007, including 346 with single vessel…
Comparison
Multivessel PCI performed in a single session… vs Infarct-related artery-only PCI, and patients…
Design
Cohort
Follow-up
median 597 days
Authors
Loading...
Multivessel PCI was associated with lower 30-day mortality than IRA-only in stable STEMI; leaves open confirmation in randomized trials.
Cohort (n=745)
Does multivessel PCI improve mortality compared to IRA-only PCI in STEMI patients with multivessel disease?
Absolute Event Rate: 2.8% vs 6.3%
p-value: p=0.023
In STEMI patients with multivessel disease without hemodynamic compromise, multivessel PCI yields good short-term results with 30-day mortality lower than IRA-only treatment.
Varani et al. (2008) conducted a cohort in ST-elevation myocardial infarction (STEMI) (n=745). Multivessel percutaneous coronary intervention (MV-PCI) vs. Infarct related artery (IRA)-only treatment was evaluated on 30-day mortality (excluding cardiogenic shock or pulmonary edema) (p=0.023). In STEMI patients without hemodynamic compromise, multivessel PCI was associated with a 30-day mortality of 2.8%, compared to 6.3% for IRA-only treatment and 1.3% for single vessel disease (P=0.023).